In addition, fucosterol significantly decreased the MAPK pathway phosphorylation cascades, including phosphorylated (p-) ERK1/2 (ES2: up to 0.2-fold, p < 0.01; OV90: up to 0.5-fold, p < 0.01), p-JNK (ES2: up to 0.3-fold, p < 0.001; OV90: up to 0.2-fold, p < 0.001), and p-P38 (ES2: up to 0.3-fold, p < 0.001; OV90: up to 0.4-fold, p < 0.001) in ES2 and OV90 cells compared with vehicle-treated ovarian cancer cells (Figure 4D–F). The gene discussed is MAPK3; the disease is ovarian carcinoma.